TEL-AVIV, Israel, Jan. 04, 2017 (GLOBE NEWSWIRE) --
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the
“Company”), a specialty biopharmaceutical company primarily focused on
the development and commercialization of late clinical-stage,
proprietary, orally-administered, small molecule drugs for
gastrointestinal and inflammatory diseases and cancer, today announced
the signing of an exclusive co-promotion agreement with a subsidiary2 of
Concordia International Corp. (NASDAQ:CXRX) (TSX:CXR) (“Concordia”), an
international specialty pharmaceutical company focused on generic and
legacy pharmaceutical products and orphan drugs, granting RedHill
certain U.S. promotion rights for Donnatal®, a prescription
oral drug used with other drugs in the treatment of irritable bowel
syndrome (irritable colon, spastic colon, mucous colitis) and acute
enterocolitis (inflammation of the small bowel)3.
Under the terms of the agreement, RedHill will be responsible for certain promotional activities related to Donnatal®. Concordia will continue to be responsible for the manufacturing and supply of Donnatal® in all territories. Donnatal® accounted for 7.7% of Concordia’s consolidated revenues in the first half of 20164. RedHill and Concordia will share the revenues generated from the promotion of Donnatal®
by RedHill based on an agreed upon split between them. The initial term
of the co-promotion agreement with Concordia is for three years.
RedHill expects to initiate gradual promotion of Donnatal® in the coming months.
SOURCE : RedHill Biopharma Ltd
No comments:
Post a Comment